Skip to main content

Table 1 Baseline characteristics of patients

From: Antiviral treatment perspective against Borna disease virus 1 infection in major depression: a double-blind placebo-controlled randomized clinical trial

Characteristic

Amantadine

Placebo

Total

P-value

(N = 16)

(N = 17)

(N = 33)

 

Age, mean ± SD, years

50.69 ± 10.18

54.67 ± 9.63

52.79 ± 9.94

0.154

Female, N (%)

12 (75)

8 (47.1)

21

 

> 1 year of college, N (%)

14 (87.5)

15 (88.2)

29

 

Recurrent major depression

10 (62.5)

10 (58.8)

20

 

Bipolar depression, N (%)

 Bipolar I

3 (18.75)

4 (23.5)

7

 

 Bipolar II

3 (18.75)

3 (17.6)

6

 

Mean number of depressive episodes per year (past 3 years prior to current episode)

1.0 ± 1.1

1.04 ± 1.2

1.02 ± 1.1

0.904

Mean duration of depressive episodes (weeks) (past 3 years prior to current episode)

25.6 ± 21

23.7 ± 18

24.6 ± 19

0.781

Duration of illness (years)

12.4 ± 9

17.6 ± 11

15.1 ± 10

0.135

Patients with antidepressant or mood stabilizing co-medication, N (%)

12 (75)

8 (47.1)

20

 

Amitriptyline

3

3

6

 

Doxepin

1

1

2

 

Mirtazapine

1

 

1

 

Clomipramine

1

 

1

 

Trimipramine

1

 

1

 

Tranylcypromine

1

 

1

 

Moclobemide

1

 

1

 

Sertraline

 

2

2

 

Paroxetine

1

1

2

 

Dibenzepine

1

 

1

 

Maprotiline

 

1

1

 

Lithium

2

2

4

 

Carbamazepine

2

2

4

 

Valproate

1

 

1

 

Lorazepam

3

1

4

 

Alprazolam

1

 

1

 

Zolpidem

 

1

1

 

Sulpirid

1

 

1

 

L-Thyroxin

 

2

2

 

Dihydroergotamine

1

 

1

 

Estrogenes

1

1

2

Â